NAMS News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

NA

Mkt Cap

$2.46B

Volume

1.45M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific SessionsNewAmsterdam Pharma announced it will present multiple data presentations on obicetrapib, its novel oral CETP inhibitor for cholesterol management, at the NLA 2026 Scientific Sessions in Chicago on June 11-14, 2026. The presentations will cover clinical trial safety assessments, efficacy data from Phase 3 trials (BROADWAY and BROOKLYN), and real-world evidence on statin intolerance. The company has also granted European commercialization rights to the Menarini Group.GlobeNewswire Inc. · Jun 3, 2026

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in JuneNewAmsterdam Pharma announced that company management will participate in investor conferences including the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The company is developing obicetrapib, an oral CETP inhibitor, for LDL-C lowering in cardiovascular disease patients, with regulatory decisions from EMA, UK, and Switzerland expected in the second half of 2026.GlobeNewswire Inc. · May 28, 2026

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NewAmsterdam Pharma's Compensation Committee approved inducement grants of 50,400 share options and 15,400 restricted stock units to five new non-executive employees. The options have an exercise price of $28.43 per share with four-year vesting, while RSUs vest over three years. These grants were made under the 2024 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).GlobeNewswire Inc. · May 1, 2026

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NewAmsterdam Pharma's Compensation Committee approved inducement grants of 15,000 share options and 3,200 restricted stock units to two non-executive new hires. The options have an exercise price of $32.81 per share with four-year vesting, while RSUs vest over three years. Both grants were made under the 2024 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).GlobeNewswire Inc. · Apr 2, 2026

NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech SummitNewAmsterdam Pharma announced that its CFO Ian Somaiya and EVP of Investor Relations Matthew Philippe will participate in a virtual fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026. The company is a late-stage biopharmaceutical firm developing obicetrapib, an oral CETP inhibitor for LDL-C lowering in cardiovascular disease patients, with EMA approval decisions expected in H2 2026.GlobeNewswire Inc. · Feb 4, 2026

NewAmsterdam (NAMS) Q2 Revenue Jumps 49%NewAmsterdam Pharma reported Q2 2025 earnings with $19.1 million in revenue, exceeding consensus estimates. The company showed progress in clinical trials for obicetrapib, a cholesterol-lowering therapy, and maintained strong cash reserves while preparing for potential European market entry.The Motley Fool · Aug 7, 2025

NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical TrialNewAmsterdam Pharma announced positive results from a pre-specified Alzheimer's disease biomarker analysis in its Phase 3 BROADWAY trial, showing statistically significant reductions in key biomarkers in both the full study population and in ApoE4 carriers. The findings support the potential of obicetrapib, a CETP inhibitor, to prevent Alzheimer's disease progression.GlobeNewswire Inc. · Jun 9, 2025

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NewAmsterdam Pharma, a late-stage biopharmaceutical company, announced the grant of inducement share options and restricted stock units to new hires, including the new Chief People Officer. The grants are aimed at incentivizing and retaining key personnel.GlobeNewswire Inc. · Jan 9, 2025

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesNewAmsterdam Pharma, a late-stage biopharmaceutical company, announced the closing of a $479.0 million public offering of ordinary shares and pre-funded warrants. The net proceeds will be used to fund the development of the company's lead product, obicetrapib, an oral LDL-lowering therapy.GlobeNewswire Inc. · Dec 13, 2024

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNewAmsterdam Pharma, a late-stage biopharmaceutical company, announced the pricing of a $416.5 million public offering of ordinary shares and pre-funded warrants. The proceeds will be used to advance the development of the company's lead product candidate, obicetrapib, for the treatment of cardiovascular disease.GlobeNewswire Inc. · Dec 12, 2024

NA

NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares

NAMS

Pay with—

Available Balance0.00

Your PositionYou don't own any NAMS yet.

Related Tickers

Earnings